home / stock / mdna:cc / mdna:cc news

MDNA:CC News and Press, Medicenna Therapeutics Corp.

Stock Information
Company Name: Medicenna Therapeutics Corp.
Stock Symbol: MDNA:CC
Market: TSXC
Website: medicenna.com
Menu
Get MDNA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
MDNA:CC - Medicenna Therapeutics Corp. GAAP EPS of -C$0.22

2026-06-26 08:51:12 ET More on Medicenna Therapeutics Corp. Medicenna Therapeutics Corp. (MDNA:CA) Presents at 2026 Bloom Burton & Co. Healthcare Investor Conference - Slideshow Medicenna launches marketed public offering of securities Historical earnings data fo...
MDNA:CC - Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors Enrolment in ABILITY-1 to b...

MDNA:CC - Expected Canadian Company Earnings on Wednesday, June 24th, 2026

AGF Management Limited Class B Non-Voting Shares (AGF.B:CA) is expected to report $0.52 for Q2 2026 Blackrock Silver Corp. (BRC:CA) is expected to report $0.01 for Q2 2026 NovaGold Resources Inc. (NG:CA) is expected to report $-0.08 for Q2 2026 Medicenna Therapeutics Corp. (MDNA:CA) i...

MDNA:CC - Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced the issuance of t...
MDNA:CC - Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses  Up to 80 patients with locally advanced melanoma will be randomized in this Investigator-sponsored, multicenter ...

MDNA:CC - Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the d...

MDNA:CC - Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused o...
MDNA:CC - Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical...

MDNA:CC - Medicenna launches marketed public offering of securities

2026-05-13 16:08:49 ET More on Medicenna Therapeutics Corp. Medicenna Therapeutics Corp. (MDNA:CA) Presents at 2026 Bloom Burton & Co. Healthcare Investor Conference - Slideshow Historical earnings data for Medicenna Therapeutics Corp. Financial information for M...

MDNA:CC - Medicenna Announces the Launch of a Marketed Public Offering of Securities

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused o...
Next 10